Doseology Sciences unit signs manufacturing deal

Executive Summary

• Doseology Sciences Inc. has executed a confidential manufacturing agreement through its U.S. subsidiary, Doseology USA Inc., with a leading North American production partner.
• The agreement marks a strategic transition from the research and development phase to commercial deployment and market readiness for the company's oral stimulant pouches.
• The selected partner is an FDA-registered, GMP-certified, and ISO 9001:2015-approved facility capable of handling formulation, blending, pouch filling, and packaging for nicotine, caffeine, and nootropic products.

Key Details

• Agreement Structure: Confidential manufacturing agreement executed by Doseology USA Inc., a wholly owned Florida subsidiary of Doseology Sciences Inc.
• Partner Qualifications:
  • Facility is FDA-registered, GMP-certified, and ISO 9001:2015-approved.
  • Provides turnkey manufacturing expertise including formulation, ingredient sourcing, blending, pouch filling, packaging, and logistics.
  • Specializes in oral pouch formats with precision control over nicotine, caffeine, and nootropic dosages, moisture, and flavor.
• Operational Capabilities:
  • Scalable production model accommodating pilot runs, regional launches, and high-volume commercial production.
  • Designed to minimize capital investment while accelerating go-to-market timelines.
  • Includes rigorous quality assurance, traceability, and labeling practices aligned with FDA and ISO standards.
• Strategic Context:
  • The company conducted extensive on-site reviews, operational assessments, and compliance audits across facilities in the United States and Canada.
  • The partnership aims to establish the commercial infrastructure and regulatory foundation required for full market entry.
  • Strategic Commercialization Adviser Patrick Sills (formerly of Swedish Match/ZYN) validated the partnership's focus on disciplined manufacturing and compliance.

Notable Quotes

• "This is much more than a manufacturing agreement; it's a defining moment as it enables Doseology to move from R&D [research and development] to commercial deployment," said Tim Corkum, president and chief operating officer of Doseology.
• "This step validates our readiness to scale... For shareholders, this milestone signals tangible execution and a disciplined pathway toward value creation," said Tim Corkum.
• "This agreement represents a pivotal step in Doseology's ability to commercialize efficiently and responsibly... This partnership validates the company's commitment to execution, quality and shareholder value," said Patrick Sills, strategic commercialization adviser.